“The Rise of Medical Science” Academic News: Professor Zang Aimin from Department of Medical Oncology of Affiliated Hospital of Hebei University/ School of Clinical Medicine scored a series of achievements in the field of malignant tumor

Recently, a drug clinical study (the multicenter and open-label Phase Ib study evaluating the efficacy and safety of QL1706 in patients with advanced malignant solid tumors) was led by the team of Prof. Zhangli and Prof. Zhao Hongyun from Sun Yat-sen University Cancer Center and hosted by the Principal Investigator (PI) of the branch center, Prof. Zang Aimin from Department of Medical Oncology of Affiliated Hospital of Hebei University/School of Clinical Medicine. They scored important achievements. QL1706 is the first bifunctional MabPair product with dual blockade of PD-1 and CTLA-4 in China, mainly targeting at patients with advanced solid tumors who failed standard therapies. It was found that QL1706 was well tolerated and demonstrated promising antitumor activity in solid tumors, especially in patients with non-small cell lung cancer, nasopharyngeal carcinoma and cervical cancer. The achievements indicate that it is a potential new option of dual-targeted immunotherapy for part of advanced malignant tumors.

Prof. Zang Aimin and her team have undertaken more than 200 projects of clinical trials from Phase I to Phase IV and scored a series of important achievements  for the current stage. The achievements of their work were published respectively in the following international authoritative academic journals: Journal of Hematology & Oncology (A1, IF=23.168), European Journal of Cancer (2022, IF=10.002), Lancet Respiratory Medicine (2022, IF=102.642), and Journal of Thoracic Oncology (2022, IF=20.121).

Here are the links of the articles: (1)https://doi.org/10.1186/s13045-023-01445-1

(2)https://pubmed.ncbi.nlm.nih.gov/34462189/

(3)https://pubmed.ncbi.nlm.nih.gov/35662408/

(4)https://pubmed.ncbi.nlm.nih.gov/35724798/